Veterinary Medicines

HIPRABOVIS-4

Authorised
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Download as PDF

Product identification

Medicine name:
HIPRABOVIS-4
Active substance:
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Target species:
  • Cattle
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
    50.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    Dose
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
    16.00
    haemagglutination inhibiting unit(s)
    /
    1.00
    Dose
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
    50.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    Dose
  • Bovine respiratory syncytial virus, strain Lym-56, Live
    4.00
    cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        0
        day
  • Subcutaneous use
    • Cattle
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AH
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • The Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 2772 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 29/11/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."